Claris Bio Emerges From Stealth With a New Investor and Prepares for Next Development Stage With Late-Stage Data Expected in 1H24
04 janv. 2024 08h00 HE
|
Claris Biotherapeutics, Inc.
Claris Bio emerges from stealth with $57 million in funding as it prepares for 1H2024 readout of late-stage study in neurotrophic keratopathy